Novo (NYSE: NVO), a Denmark-based pharmaceutical leader, has made important breakthroughs over the past decade. The company initially benefited from its advances, with the stock climbing to an all-time high in 2024. However, the company has encountered clinical and commercial setbacks since then and has lost substantial market value over the past two years. Could Novo bounce back? How might the stock perform over the next decade? Image source: The Motley Fool. Novo has been a leader in the diabetes market for decades. It continues to generate much of its sales from its diabetes products, including Ozempic and Rybelsus, among others. Novo has also become one of the top players in the anti-obesity market thanks to Wegovy. The good news for the company is that over the next decade, its core areas of expertise should expand significantly.
CryptoAlerta — análise de criptomoedas e mercado em tempo real